Quarterly Report: Carl Zei Meditec AG Grows in Ophalmology and Microsurgery

JENA/Germany, 12.08.2016. In the first nine months of fiscal year 2015/16 medical technology company Carl Zeiss Meditec AG increased its revenue by 6.7 percent to 798.6 million (adjusted for currency effects: 4.5 percent). All Strategic Business Units (SBU) and regions contributed to growth in the reporting period, however, at varying rates. Earnings before interest and taxes (EBIT) at 110.5 million (prior year: 89.5 million) developed positively, corresponding to an EBIT margin at 13.8 percent (prior year: 12.0 percent). Earnings per share were 0.83 (prior year 0.64).

Substantial growth was posted by the two strategic business units of Ophthalmology: The Ophthalmic Systems SBU (OPH) increased revenue after nine months by 7.5 percent to 304.9 million compared to 283.5 million in the same period of the previous year. Adjusted for currency effects, revenue increased by 5.0 percent. The Surgical Ophthalmology SBU (SUR) increased its revenue by 8.6 percent (adjusted for currency effects: 7.1 percent) to 280.8 million (prior year: 258.5 million).

In the Microsurgery SBU, revenue growth was 3.0 percent and mainly due to favorable exchange rates. Revenue climbed to 212.8 million, compared with 206.7 million in the same period of the previous year. Based on constant exchange rates, growth would have been 0.6 percent.

Asia Once Again Growth Engine

In the reporting regions, the major part of growth was accounted for by the APAC region in the first three quarters of the current fiscal year.

In the EMEA region, a slight increase in revenue was reported by 0.2 percent to 262.5 million (prior year: 261.9 million), whereas Germany and France enjoyed growth. However, the business trend in Middle East and Africa was declining.

Revenue in the Americas region increased by 0.9 percent to 257.3 million (prior year: 255.2 million). The strength of the US dollar had a positive effect in this region. After adjustment for currency effects, a decline by -2.9 percent was reported compared to the previous year, which was due to continued strong pressure from competition and difficult economic conditions in parts of South America.

The APAC region generated revenue of 278.7 million which is significantly higher than the year-ago figure of 231.6 million an increase by 20.3 percent. Adjusted for slight currency effects, growth would still have been 17.1 percent. The lions share of the increase came from the Chinese market as well as from Southeast Asia and South Korea; the Japanese market exhibited a sideways trend.

Dr. Ludwin Monz, CEO of Carl Zeiss Meditec AG, believes the Company is on the right track and in view of the 9-month figures confirmed the forecast for the current fiscal year with an annual revenue in the range of 1,080 - 1,120 million. "The result of the first three quarters endorses our growth strategy. In particular the innovations launched recently supported us to expand our market position, especially in Asia. In view of the recently announced consolidation to focus the organizational structure on the two core markets of the company, microsurgery and ophthalmology, he said: "We want to improve service for our customers and tap into potentials in various regional markets."

Revenue by Strategic Business Unit

Figures in EUR 000 9 Months 2014/15 9 Months 2015/16 Change from

prior year Change from

prior year

Ophthalmic Systems 283,542 304,945 7.5% 5.0%

Surgical Ophthalmology 258,506 280,813 8.6% 7.1%

Microsurgery 206,653 212,838 3.0% 0.6%

adjusted for currency effects

Revenue by Region

Figures in EUR 000 9 Months 2014/15 9 Months 2015/16 Change from

prior year Change from

prior year

EMEA 261,932 262,516 0.2% 0.6%

Americas 255,153 257,344 0.9% - 2.9%

APAC 231,616 278,736 20.3% 17.1%

adjusted for currency effects

Press Contact:

Jann Gerrit Ohlendorf

Director Corporate Communications

Carl Zeiss Meditec AG

Phone: 49 3641 220-331

Fax: 49 3641 220-332

press.meditec@zeiss.com

Sebastian Frericks

Director Investor Relations

Carl Zeiss Meditec AG

Phone: 49 3641 220-116

investors.meditec@zeiss.com

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of ZEISS is rounded off by promising future technologies such as intraoperative radiation therapy. With approx. 2,900 employees worldwide, the Group generated revenue of 1,040 million in fiscal year 2014/2015 (to 30 September).

The Group's head office is in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Companys presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For more information visit our website at:

www.zeiss.com/med

Number: 0083-2016-ENG OP

Number of Words: 885

Number

LINK:	http://applications.zeiss.com/C1256A770030BCE0/WebViewTopNewsAllE/B157...
	See more stories from zeiss

Most recent headlines